Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Non-Current Assets (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Non-Current Assets for 3 consecutive years, with $9.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 27.67% to $9.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.7 million through Dec 2025, up 86.17% year-over-year, with the annual reading at $9.8 million for FY2025, 27.67% up from the prior year.
  • Non-Current Assets hit $9.8 million in Q4 2025 for Compass Therapeutics, down from $10.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $10.5 million in Q2 2025 to a low of $2.1 million in Q2 2024.
  • Historically, Non-Current Assets has averaged $6.1 million across 3 years, with a median of $5.8 million in 2023.
  • Biggest five-year swings in Non-Current Assets: plummeted 47.17% in 2024 and later skyrocketed 408.62% in 2025.
  • Year by year, Non-Current Assets stood at $3.0 million in 2023, then surged by 155.58% to $7.7 million in 2024, then rose by 27.67% to $9.8 million in 2025.
  • Business Quant data shows Non-Current Assets for CMPX at $9.8 million in Q4 2025, $10.1 million in Q3 2025, and $10.5 million in Q2 2025.